modelA02BX03

Diagram of A02BX03

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Pirenzepine
ATC code:A02BX03
route:oral
compartments:1
dosage:100mg
volume of distribution:1.3L
clearance:110ml/min
other parameters in model implementation

Pirenzepine is a selective muscarinic M1 receptor antagonist used primarily in the past for the treatment of peptic ulcer disease and other gastric acid-related disorders. It reduces gastric acid secretion. It has largely fallen out of use and is no longer widely approved for current clinical use in many countries.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after a single oral dose.

References

  1. Bozler, G, & Hammer, R (1980). An international pharmacokinetic study on pirenzepine following a single oral dose. Scandinavian journal of gastroenterology. Supplement 66 27–33. PUBMED:https://pubmed.ncbi.nlm.nih.gov/6941374

  2. Sathirakul, K, et al., & Wise, SD (2003). Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. British journal of clinical pharmacology 56(2) 184–187. DOI:10.1046/j.1365-2125.2003.01857.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12895191

  3. Lane, HY, et al., & Chang, WH (2000). Disposition of olanzapine in Chinese schizophrenic patients. International journal of clinical pharmacology and therapeutics 38(10) 482–485. DOI:10.5414/cpp38482 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11073289

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)